Clinical Trials
23 trialsNCT04484909 2026-05-22
NBTXR3 Activated by Radiation Therapy for the Treatment of Locally Advanced or Borderline-Resectable Pancreatic Cancer
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT03528642 2026-05-13
Telaglenastat With Radiation Therapy and Temozolomide in Treating Patients With IDH-Mutated Diffuse Astrocytoma or Anaplastic Astrocytoma
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT04052555 2026-05-13
Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT03132922 2026-05-07
MAGE-A4ᶜ¹º³²T for Multi-Tumor
USWM, LLC (dba US WorldMeds)
Phase 1 Active not recruiting
NCT03228537 2026-05-01
Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT02626312 2026-04-30
Radiation Therapy in Treating Patients With Hepatocellular Carcinoma, Cholangiocarcinoma, or Liver Metastasis Who Have Impaired Liver Function
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT02595879 2026-04-29
Triapine With Chemotherapy and Radiation Therapy in Treating Patients With IB2-IVA Cervical or Vaginal Cancer
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT04460937 2026-04-29
Testing the Addition of an Anti-cancer Drug, Adavosertib, to Radiation Therapy for Patients With Incurable Esophageal and Gastroesophageal Junction Cancers
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT03044613 2026-03-23
Nivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Active not recruiting
NCT04505267 2026-03-11
NBTXR3 and Radiation Therapy for the Treatment of Inoperable Recurrent Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT04420975 2026-03-10
Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma
Jonsson Comprehensive Cancer Center
Phase 1 Active not recruiting
NCT04013542 2026-03-05
Ipilimumab and Nivolumab in Combination With Radiation Therapy in Treating Patients With Stage 2-3 Non-small Lung Cancer
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT04522336 2026-03-05
Pembrolizumab and Chemoradiotherapy for the Treatment of Unresectable Gastroesophageal Cancer
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT03514069 2026-02-19
Ruxolitinib With Radiation and Temozolomide for Grade III Gliomas and Glioblastoma
Case Comprehensive Cancer Center
Phase 1 Active not recruiting
NCT04391049 2026-01-30
Testing the Addition of the Anti-cancer Viral Therapy Telomelysinâ„¢ to Chemoradiation for Patients With Advanced Esophageal Cancer and Are Not Candidates for Surgery
NRG Oncology
Phase 1 Active not recruiting
NCT04523818 2026-01-14
Short-Course Chemoradiotherapy Followed by Chemotherapy for the Treatment of Resectable Gastric Adenocarcinoma
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT05236036 2026-01-14
Mycophenolate Mofetil in Combination With Standard of Care for the Treatment of Glioblastoma
Northwestern University
Phase 1 Active not recruiting
NCT04616248 2026-01-07
In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors
University of Southern California
Phase 1 Active not recruiting
NCT06105918 2025-12-09
Radioligand Therapy After PSMA PET Guided External Beam Radiotherapy for Treating Post-Prostatectomy Patients With Biochemically Recurrent Prostate Cancer
Emory University
Phase 1 Active not recruiting
NCT02567422 2025-12-04
Testing the Addition of M6620 (VX-970, Berzosertib) to Usual Chemotherapy and Radiation for Head and Neck Cancer
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT02023463 2025-11-25
Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer
Thomas Jefferson University
Phase 1 Active not recruiting
NCT03535350 2025-09-30
Ibrutinib With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma
Case Comprehensive Cancer Center
Phase 1 Active not recruiting
NCT04047706 2025-06-29
Nivolumab, BMS-986205, and Radiation Therapy With or Without Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma
Northwestern University
Phase 1 Active not recruiting